ImmuneTech has developed and is in the early stages of commercializing its proprietary breakthrough diagnostic technology that is based on a patented system utilizing the smallest patient sample requirements of any competitive test on the market. The company's initial application is in allergy testi…
ImmuneTech has developed and is in the early stages of commercializing its proprietary breakthrough diagnostic technology that is based on a patented system utilizing the smallest patient sample requirements of any competitive test on the market. The company's initial application is in allergy testing, a disease which is a leading cause of chronic illness and a significan tburden on the healthcare system. The minimally invasive nature of sample collection benefits the lab by extending reach to the target patient population well beyond the physician's office, facilitating sample collection at on-site health screenings such as those offered at corporations, schools, mobile clinics, walk-in clinics, retail clinics, and pharmacies. Furthermore, a consumer version of the specimen collection kit has been approved for over-the-counter sale with prepayment and direct shipment to the lab for testing. The micro-sample further facilitates extreme simplification of laboratory test procedures, reducing costs by several orders of magnitude. Overall, it offers the lab key strategic benefits such as operational efficiency, rapid turn-around of results, elevated reimbursement levels, high margin cost structure, and web based execution (ordering/test results). As such, this technology platform demonstrates broad applicability across a wide-spectrum of diagnostic testing, driving a paradigm shift in the IVD test market. Although allergy is a substantial market opportunity in and of itself, it is merely a gateway to realizing the true potential of this technology.
Team (1)
Sectors ImmuneTech serves:
Health Care
Life Sciences
Technology
Join Axial's Private M&A Platform
ImmuneTech connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
